Description
Osimertinib, marketed under the brand name TAGRISSO, It is an prescription medication that has been approved by the FDA for several uses at different dates:
November 13, 2015: For EGFR T790M mutation-positive non-small cell lung cancer
March 31, 2017: For full approval
February 16, 2024: For use with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSCLC).
What is Tagrisso (Osimertinib) ?
TAGRISSO is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutationpositive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, who have progressed on or after EGFR TKI therapy. (1) This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Osimertinib (previously known as mereletinib; trade name Tagrisso) is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Developed by AstraZeneca, the medication was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission.
How to order approved “Tagrisso (Osimertinib) for tablet” Medicine?
TAGRISSO (Osimertinib) Tablet is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing TAGRISSO and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
